| Website | Metabolex.com |
| Category | BioTech |
| Phone | (510) 293-8800 |
| Employees | |
| Description | Metabolic Disease Treatment |
Metabolex, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of type II diabetes and related metabolic disorders. The company’s products include MBX-102/JNJ 39659100, an oral small-molecule insulin sensitizer; MBX-8025, which is intended for the treatment of dyslipidemia; MBX-2982, which is an agonist of GPR119, a G-protein coupled receptor that is expressed in pancreatic islets and the gastrointestinal tract; and MBX-2044, a second generation insulin sensitizer. Metabolex, Inc. was founded in 1991 and is based in Hayward, California.
